Skip to main content Accessibility help

Effects of azelastine nasal spray on nasal and nasopharyngeal microflora

  • F Aksoy (a1), E Senturk (a1), R Doğan (a1), B Veyseller (a1), O Ozturan (a1), N Gönüllü (a2) and F Yilmaz (a2)...



Azelastine nasal spray is a topical antihistaminic drug for the symptomatic treatment of allergic rhinitis. This study aimed to investigate the effects of azelastine on nasal and nasopharyngeal microflora.


Swab samples from 25 patients prescribed azelastine nasal spray monotherapy were collected just before treatment and after 1 month of treatment. After incubation of inoculates, the number of bacteria present in cultures was measured (in colony-forming units per millilitre).


Evaluation of the number of microflora revealed increased bacterial reproduction after treatment, but this difference was not statistically significant. The use of azelastine nasal spray decreased the reproduction of three potentially pathogenic bacteria; however, it did not affect the reproduction of other potentially pathogenic bacteria.


The use of azelastine nasal spray for one month did not have a statistically significant effect on the numbers of nasal and nasopharyngeal microflora; it is therefore safe from a microbiological viewpoint.


Corresponding author

Address for correspondence: Dr Erol Senturk, Department of Otorhinolaryngology, Medical Faculty, Bezmialem Vakif University, Fatih, Istanbul, Turkey Fax: +90 212 533 2326 E-mail:


Hide All
1Horak, F, Zieglmayer, UP. Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis. Expert Rev Clin Immunol 2009;5:659–69
2Bousquet, J, Khaltaev, N, Cruz, AA, Denburg, J, Fokkens, WJ, Togias, A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(suppl 86):8160
3Zechel, HJ, Brock, N, Lenke, D, Achterrath-Tuckermann, U. Pharmacological and toxicological properties of azelastine, a novel anti-allergic agent. Arzneimittelforschung 1981;31:1184–93
4Greiff, L, Andersson, M, Svensson, C, Persson, CG. Topical azelastine has a 12-hour duration of action as assessed by histamine challenge-induced exudation of alpha 2-macroglobulin into human nasal airways. Clin Exp Allergy 1997;27:438–44
5Davies, RJ, Bagnall, AC, McCabe, RN, Calderon, MA, Wang, JH. Antihistamines: topical vs oral administration. Clin Exp Allergy 1996;26:1117
6Horak, F, Jager, S, Toth, J, Kavina, A, Marschall, K, Munzel, U et al. Azelastine in pollen-induced allergic rhinitis – a pharmacodynamic study of onset of action and efficacy. Drug Invest 1994;7:3440
7Chand, N, Pillar, J, Nolan, K, Diamantis, W, Sofia, RD. Inhibition of allergic and nonallergic leukotriene C4 formation and histamine secretion by azelastine: implication for its mechanism of action. Int Arch Allergy Appl Immunol 1989;90:6770
8Hamasaki, Y, Shafigeh, M, Yamamoto, S, Sato, R, Zaitu, M, Muro, E et al. Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol 1996;76:469–75
9Nieber, K, Baumgarten, C, Rathsack, R, Furkert, J, Laake, E, Müller, S et al. Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. Clin Exp Allergy 1993;23:6971
10Shinoda, M, Watanabe, N, Suko, T, Mogi, G, Takeyama, M. Effects of anti-allergic drugs on substance P (SP) and vasoactive intestinal peptide (VIP) in nasal secretions. Am J Rhinol 1997;11:237–41
11Ito, H, Nakamura, Y, Takagi, S, Sakai, K. Effects of azelastine on the level of serum interleukin-4 and soluble CD23 antigen in the treatment of nasal allergy. Arzneimittelforschung 1998;48:1143–7
12Ciprandi, G, Pronzato, C, Passalacqua, G, Ricca, V, Grögen, J, Mela, GS et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 1996;98:1088–96
13Berdal, JE, Bjørnholt, J, Blomfeldt, A, Smith-Erichsen, N, Bukholm, G. Patterns and dynamics of airway colonisation in mechanically-ventilated patients. Clin Microbial Infect 2007;13:476–80
14Montagnini, SD, Mamizuka, EM, Pereira, CA, Srougi, M. Microbiologic aerobic studies on normal male urethra. Urology 2000;56:207–10
15Koneman, EW, Allen, SD, Janda, WM, Schreckenberger, BC, Win, WC. Color Atlas and Text Book of Diagnostic Microbiology, 4th edn.Philadelphia: JB Lippincott, 1997
16Ratner, PH, Findlay, SR, Hampel, F, van Bavel, J, Widlitz, MD, Freitag, JJ. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol 1994;94:818–25
17Salib, JR, Howarth, PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 2003;26:863–93
18Shah, S, Berger, W, Lumry, W, La Force, C, Wheeler, W, Sacks, H. Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2009;30:628–33
19Kempuraj, D, Huang, M, Kandere, K, Boucher, W, Letourneau, R, Jeudy, S et al. Azelastine is more potent than olopatadine in inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Ann Allergy Asthma Immunol 2002;88:501–6
20Matsuo, S, Takayama, S. Influence of the anti-allergic agent, azelastine, on tumor necrosis factor-alpha (TNF-α) secretion from cultured mouse mast cells. In Vivo 1998;12:481–4
21Beck, G, Mansur, A, Afzal, M et al. Effect of azelastine nasal spray on mediators of inflammation in patients with seasonal allergic rhinitis (SAR). Presented at the 56th annual meeting of the American Academy of Allergy, Asthma, and Immunology, San Diego, CA, 3–8 March 2000.
22Yoneda, K, Yamamoto, T, Ueta, E, Ueta, E, Osaki, T. Suppression by azelastine hydrochloride of NF-κB activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 1997;73:145–53
23Busse, W, Randley, B, Sedgwick, J. The effect of azelastine on neutrophil and eosinophil generation of superoxide. J Allergy Clin Immunol 1989;83:400–5
24Umeki, S. Effects of anti-allergic drops on human neutrophil superoxide-generating NADPH oxidase. Biochem Pharmacol 1992;43:1109–17
25Glück, U, Gebbers, JO. Ingested probiotics reduce nasal colonization with pathogenic bacteria (Staphylococcus aureus, Streptococcus pneumoniae, and beta-hemolytic streptococci). Am J Clin Nutr 2003;77:517–20
26Smith, CL, Kreutner, W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 1998;48:956–60
27Aksoy, F, Demirhan, H, Bayraktar, , Yıldırım, YS, Ozturan, O, Gönüllü, N et al. Effect of nasal mometasone furoate on the nasal and nasopharyngeal flora. Auris Nasus Larynx 2012;39:180–5



Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed